{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Ftheidi.simplecast.com%2Fepisodes%2Fwhy-prior-authorization-matters-for-pharma-P9Ln5Z58","width":444,"version":"1.0","type":"rich","title":"Why Prior Authorization Matters for Pharma","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/9660dd78-6154-402f-87c9-4f85da5cd51a/0d2a0f98-2268-4f07-93dc-0f411170596e/masthead-square-the-idi.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/040be71a-d0aa-4915-88f5-ea3c9eb4fa07\" height=\"200\" width=\"100%\" title=\"Why Prior Authorization Matters for Pharma\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Prior authorizations are a frustrating hurdle for patients who often need immediate treatment – including those in need of prescription drugs. Guests John Hennessy of Valuate and Syam Palakurthy of SamaCare join The IDI to explain the current state of prior authorization – and what’s at stake for pharma and market access. \n"}